- Conditions
- Dry Eye Disease
- Interventions
- OTX-CSI, Placebo Vehicle
- Drug · Other
- Lead sponsor
- Ocular Therapeutix, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 153 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 15
- States / cities
- Garden Grove, California • Inglewood, California • Mission Hills, California + 11 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 217–240
of 1,069
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Healthy Adult Participants
- Interventions
- TBD11, Placebo
- Drug
- Lead sponsor
- Gates Medical Research Institute
- Other
- Eligibility
- 19 Years to 55 Years
- Enrollment
- 124 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- Lincoln, Nebraska
- Conditions
- Safety
- Interventions
- MRX-8, Placebo
- Drug
- Lead sponsor
- MicuRx
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 69 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2021
- U.S. locations
- 1
- States / cities
- Tempe, Arizona
- Conditions
- Pharmacokinetics
- Interventions
- Hutrukin, Placebo
- Biological
- Lead sponsor
- XBiotech, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- Austin, Texas
- Conditions
- FXI
- Interventions
- FXI-GalNAc-siRNA, Placebo
- Drug · Other
- Lead sponsor
- Sirnaomics
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2027
- U.S. locations
- 1
- States / cities
- Creve Coeur, Missouri
- Conditions
- Asthma in Children
- Interventions
- Inulin
- Drug
- Lead sponsor
- Phoenix Children's Hospital
- Other
- Eligibility
- 6 Years to 17 Years
- Enrollment
- 105 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Phoenix, Arizona
- Conditions
- Opioid Induced Constipation
- Interventions
- TD-1211, Placebo
- Drug
- Lead sponsor
- Glycyx Therapeutics
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 95 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 1
- States / cities
- Pasadena, California
- Conditions
- Neoplasms, Breast
- Interventions
- Niraparib, Placebo
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 24
- States / cities
- Burbank, California • Duarte, California • Palo Alto, California + 20 more
- Conditions
- COVID-19
- Interventions
- Sarilumab, Placebo
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,912 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020
- U.S. locations
- 62
- States / cities
- Los Angeles, California • Sacramento, California • Santa Monica, California + 42 more
- Conditions
- Schizophrenia, Major Depressive Disorder (MDD), Bipolar Disorder
- Interventions
- SEP-380135, Placebo
- Drug
- Lead sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 43 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- Los Alamitos, California
- Conditions
- Moderate to Severe Ulcerative Colitis
- Interventions
- Induction- PF-06480605 50 mg SC Q4W, Induction- PF-06480605 150 mg SC Q4W, Induction- PF-06480605 450 mg SC Q4W, Induction- Placebo SC Q4W, Chronic- PF-06480605 50 mg SC Q4W, Chronic- PF-06480605 150 mg SC Q4W, Chronic- PF-06480605 450 mg SC Q4W
- Drug · Other
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 246 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 55
- States / cities
- Dothan, Alabama • Little Rock, Arkansas • Newport Beach, California + 20 more
- Conditions
- Obesity, Overweight, or Chronic Weight Management
- Interventions
- Aleniglipron or Placebo, Aleniglipron
- Drug
- Lead sponsor
- Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics
- Industry
- Eligibility
- 18 Years to 79 Years
- Enrollment
- 230 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 39
- States / cities
- Phoenix, Arizona • Anaheim, California • Los Angeles, California + 33 more
- Conditions
- Coronary Disease
- Interventions
- RUC-4 Compound
- Drug
- Lead sponsor
- CeleCor Therapeutics
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 44 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
- Conditions
- Crohn's Disease
- Interventions
- Placebo, BMS-936557 (Anti-IP-10 Antibody)
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 121 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 10
- States / cities
- Santa Monica, California • Winter Park, Florida • Hammond, Louisiana + 7 more
- Conditions
- Bronchopulmonary Dysplasia of Newborn
- Interventions
- Sildenafil, Placebo
- Drug
- Lead sponsor
- Christoph Hornik
- Other
- Eligibility
- Up to 29 Weeks
- Enrollment
- 125 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 25
- States / cities
- Little Rock, Arkansas • San Diego, California • Washington D.C., District of Columbia + 19 more
- Conditions
- Healthy Volunteers, Alzheimer Disease
- Interventions
- LY3202626, Placebo (Part A, B, C), Itraconazole
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 20 Years and older
- Enrollment
- 94 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2016
- U.S. locations
- 1
- States / cities
- Glendale, California
- Conditions
- Overweight and Obesity
- Interventions
- WVE-007
- Drug
- Lead sponsor
- Wave Life Sciences USA, Inc.
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 296 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Transfusion-dependent Alpha-Thalassemia, Transfusion-dependent Beta-Thalassemia
- Interventions
- Mitapivat Matched Placebo, Mitapivat
- Drug
- Lead sponsor
- Agios Pharmaceuticals, Inc.
- Industry
- Eligibility
- 1 Year to 17 Years
- Enrollment
- 54 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2032
- U.S. locations
- 4
- States / cities
- Atlanta, Georgia • New York, New York • Philadelphia, Pennsylvania + 1 more
- Conditions
- HIV-1-infection
- Interventions
- PENNVAX-GP, INO-6145, INO-9012, CELLECTRA® 2000
- Biological · Device
- Lead sponsor
- Steven Deeks
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 56 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 2
- States / cities
- Los Angeles, California • San Francisco, California
- Conditions
- Healthy Volunteers, Primary Sclerosing Cholangitis
- Interventions
- TAK-781, Placebo
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years to 68 Years
- Enrollment
- 134 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
- Conditions
- Healthy Volunteers
- Interventions
- ASP1617, Placebo
- Drug
- Lead sponsor
- Astellas Pharma Global Development, Inc.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 97 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2021
- U.S. locations
- 1
- States / cities
- Glendale, California
- Conditions
- Muscle Spasticity
- Interventions
- XP19986 SR1, 10 mg BID, XP19986 SR1, 20 mg BID, XP19986 SR1, 30 mg BID, Placebo
- Drug
- Lead sponsor
- XenoPort, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 37 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 11
- States / cities
- Downey, California • Gilroy, California • Pasadena, California + 8 more
- Conditions
- Primary Four Repeat Tauopathies (4RT), Corticobasal Syndrome (CBS), Progressive Supranuclear Palsy (PSP), Corticobasal Degeneration (CBD)
- Interventions
- TPI 287 2 mg/m2, TPI-287 20 mg/m2, Placebo, TPI-287 6.3 mg/m2
- Drug
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 50 Years to 85 Years
- Enrollment
- 44 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2019
- U.S. locations
- 2
- States / cities
- Birmingham, Alabama • San Francisco, California
- Conditions
- Healthy Participants
- Interventions
- AZD6234, Placebo
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 142 Years
- Enrollment
- 104 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2026
- U.S. locations
- 2
- States / cities
- Glendale, California • Brooklyn, Maryland